<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02561000</url>
  </required_header>
  <id_info>
    <org_study_id>TMC-PZ128-02</org_study_id>
    <secondary_id>P50HL110789</secondary_id>
    <nct_id>NCT02561000</nct_id>
  </id_info>
  <brief_title>Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention</brief_title>
  <acronym>TRIP-PCI</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention- Thrombin Receptor Inhibitory Pepducin in PCI (TRIP-PCI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>RTI International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inova Fairfax Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The object of the study is to determine whether different doses of PZ-128, when added to&#xD;
      standard medical care in persons undergoing cardiac catheterization/percutaneous coronary&#xD;
      intervention, will increase the risk of bleeding.&#xD;
&#xD;
      A secondary objective is to determine whether patients treated with PZ-128 have fewer cardiac&#xD;
      events such as heart attack, bypass surgery or stroke compared with those persons treated&#xD;
      with the standard of care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 27, 2016</start_date>
  <completion_date type="Actual">September 17, 2019</completion_date>
  <primary_completion_date type="Actual">September 17, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First Occurrence of Major Plus Minor Thrombolysis in Myocardial Infarction (TIMI) Bleeding Events; Number/Percentage of Observed Participants With Outcome Measure Events During the Study (Primary Safety)</measure>
    <time_frame>From initiation of study drug up to 30 days following study drug</time_frame>
    <description>All suspected bleeding events positively adjudicated by CEC in a blinded fashion, were used in the reporting of the number/percentage of observed participants with a first occurrence of a TIMI major or minor bleeding event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>First Occurrence of Major Adverse Cardiovascular Event (MACE); Number/Percentage of Observed Participants With Outcome Measure Events During the Study (Secondary Efficacy)</measure>
    <time_frame>From randomization up to 30 days following study drug</time_frame>
    <description>All suspected MACE events positively adjudicated by Clinical Events Committee (CEC) in a blinded fashion, were used in the reporting of the number/percentage of observed participants with a first occurrence of the composite cardiovascular (CV) outcome measure comprised of CV death, non-fatal Myocardial Infarction (MI), non-fatal stroke (ischemic, hemorrhagic or unknown), recurrent ischemia requiring hospitalization, or urgent coronary revascularization. The number/percentage of observed participants with outcome measure events during the study were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First Occurrence of Major Adverse Cardiovascular Event (MACE); Number/Percentage of Observed Participants With Outcome Measure Events During the Study (Secondary Efficacy)</measure>
    <time_frame>From randomization up to 90 days following study drug</time_frame>
    <description>All suspected MACE events positively adjudicated by Clinical Events Committee (CEC) in a blinded fashion, were used in the reporting of the number/percentage of observed participants with a first occurrence of the composite cardiovascular (CV) outcome measure comprised of CV death, non-fatal Myocardial Infarction (MI), non-fatal stroke (ischemic, hemorrhagic or unknown), recurrent ischemia requiring hospitalization, or urgent coronary revascularization.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Arterial Occlusive Diseases</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Disease</condition>
  <condition>Arteriosclerosis</condition>
  <condition>Heart Diseases</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Vascular Diseases</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>PZ-128 0.3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PZ-128, 0.3 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PZ-128 0.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PZ-128, 0.5 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PZ-128</intervention_name>
    <arm_group_label>PZ-128 0.3 mg/kg</arm_group_label>
    <arm_group_label>PZ-128 0.5 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject is at least 18 years of age and may be of either sex/gender and of any&#xD;
             race and ethnicity.&#xD;
&#xD;
          2. The subject is scheduled to undergo non-emergent PCI or non-emergent cardiac&#xD;
             catheterization with the intention of performing PCI. The following classifications of&#xD;
             the urgency of the procedure at the time the operator decides to perform it will be&#xD;
             used for randomization stratification:&#xD;
&#xD;
               -  Elective: The cardiac catheterization procedure ± PCI can be performed on an&#xD;
                  outpatient basis or during a subsequent hospitalization without significant risk&#xD;
                  of MI or death. For stable inpatients, this is a procedure that is performed&#xD;
                  during the hospitalization for convenience and ease of scheduling only and not&#xD;
                  because the subject's clinical situation demands that the procedure be performed&#xD;
                  prior to discharge.&#xD;
&#xD;
             OR&#xD;
&#xD;
               -  Urgent: The cardiac catheterization ± PCI procedure should be performed on an&#xD;
                  inpatient basis and before discharge because of significant concerns about the&#xD;
                  risk of myocardial ischemia, MI and/or death. For subjects who are outpatients or&#xD;
                  in the emergency department at the time that the cardiac catheterization is&#xD;
                  requested, this is a procedure that would warrant hospital admission based on&#xD;
                  clinical presentation.&#xD;
&#xD;
          3. There is no anticipation that the subject would require treatment with a GP IIb/IIIa&#xD;
             inhibitor prior to the initiation of the cardiac catheterization ± PCI procedure if&#xD;
             the subject were not a participant in the current research study, and no anticipation&#xD;
             of use during the procedure.&#xD;
&#xD;
          4. The subject is willing and able to give appropriate informed consent and complete all&#xD;
             study-related procedures, and able to adhere to dosing and visit schedules (i.e.,&#xD;
             subject signs an approved informed consent document(s) and provides HIPAA&#xD;
             authorization);&#xD;
&#xD;
          5. The subject will undergo all of the pre-enrollment parameters according to the study&#xD;
             protocol prior to randomization and have them completed within 14 days prior to the&#xD;
             scheduled cardiac catheterization ± PCI procedure and study drug administration.&#xD;
&#xD;
          6. Women of childbearing potential (all postmenarchal women who are &lt;1 year menopausal or&#xD;
             who have not had surgical sterilization or a hysterectomy are considered to be women&#xD;
             of child-bearing potential) must agree to use a medically accepted method of&#xD;
             contraception from the time written informed consent is given up until 90 days&#xD;
             following the study drug administration.&#xD;
&#xD;
        Subject Exclusion Criteria:&#xD;
&#xD;
        The subject will be excluded from entry if any of the criteria listed below are met:&#xD;
&#xD;
        (General Exclusions)&#xD;
&#xD;
          1. Subject is pregnant, intends to become pregnant or is breast-feeding (all women of&#xD;
             child-bearing potential must have a negative pregnancy test result confirmed prior to&#xD;
             randomization and it must be repeated to be within 24 hours prior to the study drug&#xD;
             administration if necessary).&#xD;
&#xD;
          2. Any of the following allergy history(s):&#xD;
&#xD;
               -  History of an allergic reaction* or contraindication to any of the following&#xD;
                  protocol-directed drugs: aspirin, heparin, P2Y12 inhibitor (clopidogrel,&#xD;
                  prasugrel, ticagrelor), antihistamines (benadryl, famotidine); or&#xD;
&#xD;
               -  History of an allergic reaction* to contrast media; or&#xD;
&#xD;
               -  History of an allergic reaction* to a drug which required emergency medical&#xD;
                  treatment;&#xD;
&#xD;
               -  History of an allergic reaction* to a Hymenoptera sting which currently&#xD;
                  necessitates the subject to carry an EpiPen/injector or the subject has been&#xD;
                  prescribed one to treat an allergic reaction to a sting.&#xD;
&#xD;
                    -  An allergic (anaphylactic) reaction is characterized by an adverse local or&#xD;
                       general response from exposure to an allergen involving skin/mucosal tissue&#xD;
                       manifestations (hives, pruritus, flushing, angioedema), and/or respiratory&#xD;
                       compromise (dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory&#xD;
                       flow, hypoxemia), and/or hemodynamic effects (hypo/hypertension, hypotonia,&#xD;
                       syncope).&#xD;
&#xD;
          3. Participation in another research study of investigational therapy (drug or device)&#xD;
             within the past 30 days prior to randomization or planned use of other investigational&#xD;
             therapy(s) during this research study (until 90 days following the study drug&#xD;
             administration).&#xD;
&#xD;
          4. Subject is part of the study staff personnel directly involved with this trial, or is&#xD;
             a family member of the study staff (clinical site or sponsor).&#xD;
&#xD;
          5. Prior enrollment (randomization) in this research study.&#xD;
&#xD;
          6. Any condition which could interfere with, or the treatment for which might interfere&#xD;
             with, the conduct of the research study or which would, in the opinion of the&#xD;
             investigator, unacceptably increase the subject's risk by participating in the&#xD;
             research study. This would include, but is not limited to alcoholism, drug dependency&#xD;
             or abuse, psychiatric disease, epilepsy or any unexplained blackouts.&#xD;
&#xD;
             (Exclusionary Prior/Concomitant Conditions)&#xD;
&#xD;
          7. Evidence of an ST-segment elevation myocardial infarction (STEMI) on presentation or&#xD;
             during current hospitalization or a history of STEMI within the past 30 days prior to&#xD;
             randomization.&#xD;
&#xD;
          8. Subject is scheduled to undergo PCI for known unprotected left main coronary artery&#xD;
             (LMCA) disease (i.e., left main stenosis ≥50% not protected by at least 1 patent&#xD;
             bypass graft).&#xD;
&#xD;
          9. Any history of a prior stroke (hemorrhagic or ischemic) or transient ischemic attack&#xD;
             (TIA) of any etiology.&#xD;
&#xD;
         10. Cardiogenic or any type of shock on presentation or during current hospitalization&#xD;
             (i.e., systolic blood pressure &lt;90 mm Hg requiring vasopressor or hemodynamic&#xD;
             support).&#xD;
&#xD;
         11. History of heparin-induced thrombocytopenia (HIT).&#xD;
&#xD;
         12. Any active bleeding within the past 30 days prior to randomization.&#xD;
&#xD;
         13. Any condition or personal belief (e.g., Jehovah's Witness) which would interfere with&#xD;
             the subject's ability or willingness to undergo a blood transfusion.&#xD;
&#xD;
         14. Any of the following conditions associated with increased risk of bleeding:&#xD;
&#xD;
               1. history of intracranial, intraocular, spinal, retroperitoneal or atraumatic&#xD;
                  intra- articular bleeding;&#xD;
&#xD;
               2. gastrointestinal bleeding within the past 30 days prior to randomization;&#xD;
&#xD;
               3. gastric or duodenal ulcer disease verified by endoscopy or barium meal contrast&#xD;
                  technique within the past 6 months prior to randomization;&#xD;
&#xD;
               4. history of bleeding disorder or diathesis;&#xD;
&#xD;
               5. major surgical procedure or trauma within the past 60 days prior to randomization&#xD;
                  or a planned surgical procedure to take place within 30 days following the study&#xD;
                  drug administration;&#xD;
&#xD;
               6. history or suspicion of intracranial neoplasm, arteriovenous malformation, or&#xD;
                  aneurysm; or&#xD;
&#xD;
               7. clinical finding(s) in the judgment of the investigator that poses an increased&#xD;
                  risk of bleeding.&#xD;
&#xD;
         15. Sustained severe hypertension: systolic blood pressure &gt;185 mm Hg or diastolic blood&#xD;
             pressure &gt;105 mm Hg with or without anti-hypertensive treatment (as demonstrated by&#xD;
             repeated BP measurements &gt;185/105 mm Hg including the final BP measurement before&#xD;
             randomization).&#xD;
&#xD;
         16. Hypotension: systolic blood pressure &lt;95 mm Hg (as demonstrated by repeated systolic&#xD;
             BP measurements &lt;95 mm Hg including the final systolic BP measurement prior to&#xD;
             randomization).&#xD;
&#xD;
         17. Known active hepatobiliary disease, or known unexplained persistent increase in serum&#xD;
             alanine aminotransferase (ALT) or aspartate aminotransferase (AST) activity to ≥2.5&#xD;
             times the upper limit of the reference range within the past 30 days prior to&#xD;
             randomization.&#xD;
&#xD;
         18. Hemoglobin &lt;10 g/dL or hematocrit &lt;30%.&#xD;
&#xD;
         19. Platelet count &lt;75,000/mm3.&#xD;
&#xD;
         20. Stage 4-5 Chronic Kidney Disease (National Kidney Foundation) or on dialysis.&#xD;
&#xD;
         21. Active sepsis or suspected sepsis.&#xD;
&#xD;
         22. Body weight &lt;60 kg or &gt;175 kg.&#xD;
&#xD;
         23. Current evidence of invasive cancer (persistent disease excluding basal cell carcinoma&#xD;
             of the skin) or treatment for invasive cancer within the past 6 months prior to&#xD;
             randomization.&#xD;
&#xD;
         24. Left ventricular ejection fraction &lt;25% if known (any imaging technique) or New York&#xD;
             Heart Association (NYHA) Class IV congestive heart failure.&#xD;
&#xD;
             (Exclusionary Prior/Concomitant/Anticipated Medication/Therapy)&#xD;
&#xD;
         25. Coronary interventional procedure of any kind within the past 30 days prior to&#xD;
             randomization.&#xD;
&#xD;
         26. Anticipated subsequent staged multi-vessel PCI within 30 days following the study drug&#xD;
             administration.&#xD;
&#xD;
         27. History of treatment with any parenteral GP IIb/IIIa inhibitor (GPI) within the past&#xD;
             30 days prior to randomization. (As stated in the Inclusion section, the planned&#xD;
             treatment with a GPI prior to initiation of the cardiac catheterization ± PCI is not&#xD;
             allowed; however, GPI for thrombotic bailout may be used during the PCI at the&#xD;
             investigator's discretion).&#xD;
&#xD;
         28. Concurrent or anticipated treatment with a parenteral direct thrombin inhibitor (e.g.,&#xD;
             bivalirudin) for the cardiac catheterization ± PCI procedure.&#xD;
&#xD;
         29. History of treatment with another PAR1 inhibitor within the past 60 days prior to&#xD;
             randomization or the concurrent/anticipated use after randomization up until 30 days&#xD;
             following the study drug administration.&#xD;
&#xD;
         30. History of treatment with another IV anti-platelet drug within 30 days prior to&#xD;
             randomization or the concurrent/anticipated use after randomization up until 30 days&#xD;
             following the study drug administration.&#xD;
&#xD;
         31. Any of the following anticoagulant or thrombolytic/fibrinolytic treatment(s):&#xD;
&#xD;
               -  History of treatment with warfarin within 5 days prior to randomization or the&#xD;
                  concurrent/anticipated use after randomization up until 2 days following the&#xD;
                  study drug administration; or&#xD;
&#xD;
               -  History of treatment with oral Factor Xa or direct thrombin inhibitors within 2&#xD;
                  days prior to randomization or the concurrent/anticipated use after randomization&#xD;
                  up until 2 days following the study drug administration; or&#xD;
&#xD;
               -  History of treatment with thrombolytic/fibrinolytic agents within 7 days prior to&#xD;
                  randomization or the concurrent/anticipated use of any of those agents after&#xD;
                  randomization up until 30 days following the study drug administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Athan Kuliopulos, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Heart and Vascular Institute, Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gurbel PA, Bliden KP, Turner SE, Tantry US, Gesheff MG, Barr TP, Covic L, Kuliopulos A. Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. Arterioscler Thromb Vasc Biol. 2016 Jan;36(1):189-97. doi: 10.1161/ATVBAHA.115.306777.</citation>
    <PMID>26681756</PMID>
  </reference>
  <results_reference>
    <citation>Rana R, Huang T, Koukos G, Fletcher EK, Turner SE, Shearer A, Gurbel PA, Rade JJ, Kimmelstiel CD, Bliden KP, Covic L, Kuliopulos A. Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2018 Jun;38(6):1368-1380. doi: 10.1161/ATVBAHA.118.310967. Epub 2018 Apr 5.</citation>
    <PMID>29622563</PMID>
  </results_reference>
  <results_reference>
    <citation>Kuliopulos A, Gurbel PA, Rade JJ, Kimmelstiel CD, Turner SE, Bliden KP, Fletcher EK, Cox DH, Covic L; TRIP-PCI Investigators. PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study. Arterioscler Thromb Vasc Biol. 2020 Dec;40(12):2990-3003. doi: 10.1161/ATVBAHA.120.315168. Epub 2020 Oct 8.</citation>
    <PMID>33028101</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 24, 2015</study_first_submitted>
  <study_first_submitted_qc>September 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2015</study_first_posted>
  <results_first_submitted>January 25, 2021</results_first_submitted>
  <results_first_submitted_qc>February 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 9, 2021</results_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platelets</keyword>
  <keyword>Platelet Aggregation Inhibitors</keyword>
  <keyword>Protease-Activated Receptor 1</keyword>
  <keyword>Hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 4, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT02561000/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>NCT02561000: Study TMC-PZ128-02 (TRIP-PCI Trial) was conducted at 3 centers in the U.S. between 27 May 2016 and 25 May 2018. A total of 3056 patients were screened for study and 100 patients were randomly assigned to treatment.</recruitment_details>
      <pre_assignment_details>Of the 3056 patients screened for study, 2956 patients were screening failures and 100 patients were randomly assigned to treatment. Of the 100 patients, 3 never received study drug (2 withdrew immediately following randomization and 1 experienced an adverse event pre-dose), leaving 97 patients valid for the primary safety analysis. All randomized patients with at least 1 follow-up assessment (98 patients) were included in the intent-to-treat (ITT) analysis set for secondary efficacy analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion&#xD;
Placebo</description>
        </group>
        <group group_id="P2">
          <title>PZ-128 0.3 mg/kg</title>
          <description>PZ-128, 0.3 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion&#xD;
PZ-128</description>
        </group>
        <group group_id="P3">
          <title>PZ-128 0.5 mg/kg</title>
          <description>PZ-128, 0.5 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion&#xD;
PZ-128</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="35">Includes 1 additional patient who was assigned PZ-128 0.3 mg/kg but received placebo in error (evaluated as placebo for primary safety outcome and adverse events).</participants>
                <participants group_id="P2" count="31">Excludes 4 patients who did not receive the study drug as allocated: 1 patient received placebo in error and was evaluated as placebo for primary safety outcome and adverse events; 2 patients withdrew full consent immediately after randomization prior to receiving any study drug; and 1 patient had an adverse event shortly after randomization prior to receiving any study drug.</participants>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-to-Treat (ITT) Population at 30 Days</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="33">Excludes 2 patients who withdrew full consent immediately after randomization.</participants>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-to-Treat (ITT) Population at 90 Days</title>
              <participants_list>
                <participants group_id="P1" count="33">Excludes 1 patient who withdrew consent for follow-up 21 days after study drug dosing.</participants>
                <participants group_id="P2" count="31">Excludes 4 patients: 2 patients withdrew full consent immediately after randomization; 1 patient followed only for 30 day ITT outcome (did not receive any study drug due to adverse event post randomization); and 1 patient withdrew consent for follow-up 7 days after study drug dosing.</participants>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion&#xD;
Placebo</description>
        </group>
        <group group_id="B2">
          <title>PZ-128 0.3 mg/kg</title>
          <description>PZ-128, 0.3 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion&#xD;
PZ-128</description>
        </group>
        <group group_id="B3">
          <title>PZ-128 0.5 mg/kg</title>
          <description>PZ-128, 0.5 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion&#xD;
PZ-128</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="12.1"/>
                    <measurement group_id="B2" value="62.4" spread="11.0"/>
                    <measurement group_id="B3" value="63.2" spread="8.6"/>
                    <measurement group_id="B4" value="61.5" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>First Occurrence of Major Plus Minor Thrombolysis in Myocardial Infarction (TIMI) Bleeding Events; Number/Percentage of Observed Participants With Outcome Measure Events During the Study (Primary Safety)</title>
        <description>All suspected bleeding events positively adjudicated by CEC in a blinded fashion, were used in the reporting of the number/percentage of observed participants with a first occurrence of a TIMI major or minor bleeding event.</description>
        <time_frame>From initiation of study drug up to 30 days following study drug</time_frame>
        <population>The Safety population included randomized participants who received any amount of the study drug dose of the double-blind IP infusion (summarized and analyzed as treated). Four patients assigned to PZ-128 0.3 mg/kg did not receive randomized treatment allocation: 1 patient received placebo in error and was evaluated as placebo for primary safety outcome and adverse events; 2 patients withdrew consent right after randomization; and 1 patient had an adverse event prior to receiving any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>PZ-128 0.3 mg/kg</title>
            <description>PZ-128, 0.3 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion&#xD;
PZ-128</description>
          </group>
          <group group_id="O3">
            <title>PZ-128 0.5 mg/kg</title>
            <description>PZ-128, 0.5 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion&#xD;
PZ-128</description>
          </group>
        </group_list>
        <measure>
          <title>First Occurrence of Major Plus Minor Thrombolysis in Myocardial Infarction (TIMI) Bleeding Events; Number/Percentage of Observed Participants With Outcome Measure Events During the Study (Primary Safety)</title>
          <description>All suspected bleeding events positively adjudicated by CEC in a blinded fashion, were used in the reporting of the number/percentage of observed participants with a first occurrence of a TIMI major or minor bleeding event.</description>
          <population>The Safety population included randomized participants who received any amount of the study drug dose of the double-blind IP infusion (summarized and analyzed as treated). Four patients assigned to PZ-128 0.3 mg/kg did not receive randomized treatment allocation: 1 patient received placebo in error and was evaluated as placebo for primary safety outcome and adverse events; 2 patients withdrew consent right after randomization; and 1 patient had an adverse event prior to receiving any study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>First Occurrence of Major Adverse Cardiovascular Event (MACE); Number/Percentage of Observed Participants With Outcome Measure Events During the Study (Secondary Efficacy)</title>
        <description>All suspected MACE events positively adjudicated by Clinical Events Committee (CEC) in a blinded fashion, were used in the reporting of the number/percentage of observed participants with a first occurrence of the composite cardiovascular (CV) outcome measure comprised of CV death, non-fatal Myocardial Infarction (MI), non-fatal stroke (ischemic, hemorrhagic or unknown), recurrent ischemia requiring hospitalization, or urgent coronary revascularization. The number/percentage of observed participants with outcome measure events during the study were reported.</description>
        <time_frame>From randomization up to 30 days following study drug</time_frame>
        <population>The Intent-to-treat (ITT) population included all randomized participants, regardless of study drug intake, who underwent at least 1 follow-up assessment within 30 days after study drug dosing. Two patients (PZ-128 0.3 mg/kg) could not be evaluated for the 30-day outcome due to complete study withdrawal shortly after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>PZ-128 0.3 mg/kg</title>
            <description>PZ-128, 0.3 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion&#xD;
PZ-128</description>
          </group>
          <group group_id="O3">
            <title>PZ-128 0.5 mg/kg</title>
            <description>PZ-128, 0.5 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion&#xD;
PZ-128</description>
          </group>
        </group_list>
        <measure>
          <title>First Occurrence of Major Adverse Cardiovascular Event (MACE); Number/Percentage of Observed Participants With Outcome Measure Events During the Study (Secondary Efficacy)</title>
          <description>All suspected MACE events positively adjudicated by Clinical Events Committee (CEC) in a blinded fashion, were used in the reporting of the number/percentage of observed participants with a first occurrence of the composite cardiovascular (CV) outcome measure comprised of CV death, non-fatal Myocardial Infarction (MI), non-fatal stroke (ischemic, hemorrhagic or unknown), recurrent ischemia requiring hospitalization, or urgent coronary revascularization. The number/percentage of observed participants with outcome measure events during the study were reported.</description>
          <population>The Intent-to-treat (ITT) population included all randomized participants, regardless of study drug intake, who underwent at least 1 follow-up assessment within 30 days after study drug dosing. Two patients (PZ-128 0.3 mg/kg) could not be evaluated for the 30-day outcome due to complete study withdrawal shortly after randomization.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>First Occurrence of Major Adverse Cardiovascular Event (MACE); Number/Percentage of Observed Participants With Outcome Measure Events During the Study (Secondary Efficacy)</title>
        <description>All suspected MACE events positively adjudicated by Clinical Events Committee (CEC) in a blinded fashion, were used in the reporting of the number/percentage of observed participants with a first occurrence of the composite cardiovascular (CV) outcome measure comprised of CV death, non-fatal Myocardial Infarction (MI), non-fatal stroke (ischemic, hemorrhagic or unknown), recurrent ischemia requiring hospitalization, or urgent coronary revascularization.</description>
        <time_frame>From randomization up to 90 days following study drug</time_frame>
        <population>The Intent-to-treat (ITT) population included all randomized participants, regardless of study drug intake, who underwent at least 1 follow-up assessment after 30 days up until 90 days after study drug dosing. 5 patients could not be evaluated for the 90-day outcome: 1 placebo withdrew at 21 d; 2 PZ-128 0.3 mg/kg withdrew post randomization; 1 PZ-128 0.3 mg/kg withdrew at 7 d; and 1 PZ-128 0.3 mg/kg patient was followed only for 30 d ITT outcome (no study drug due to AE post randomization).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>PZ-128 0.3 mg/kg</title>
            <description>PZ-128, 0.3 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion&#xD;
PZ-128</description>
          </group>
          <group group_id="O3">
            <title>PZ-128 0.5 mg/kg</title>
            <description>PZ-128, 0.5 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion&#xD;
PZ-128</description>
          </group>
        </group_list>
        <measure>
          <title>First Occurrence of Major Adverse Cardiovascular Event (MACE); Number/Percentage of Observed Participants With Outcome Measure Events During the Study (Secondary Efficacy)</title>
          <description>All suspected MACE events positively adjudicated by Clinical Events Committee (CEC) in a blinded fashion, were used in the reporting of the number/percentage of observed participants with a first occurrence of the composite cardiovascular (CV) outcome measure comprised of CV death, non-fatal Myocardial Infarction (MI), non-fatal stroke (ischemic, hemorrhagic or unknown), recurrent ischemia requiring hospitalization, or urgent coronary revascularization.</description>
          <population>The Intent-to-treat (ITT) population included all randomized participants, regardless of study drug intake, who underwent at least 1 follow-up assessment after 30 days up until 90 days after study drug dosing. 5 patients could not be evaluated for the 90-day outcome: 1 placebo withdrew at 21 d; 2 PZ-128 0.3 mg/kg withdrew post randomization; 1 PZ-128 0.3 mg/kg withdrew at 7 d; and 1 PZ-128 0.3 mg/kg patient was followed only for 30 d ITT outcome (no study drug due to AE post randomization).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Non-serious Adverse Events (AEs) were collected from signature of the informed consent form until 30 days post study drug regardless of relationship to Investigational Product (IP). All Serious Adverse Events (SAEs) were collected from signature of the informed consent form until the end of study (90 days post study drug) regardless of relationship to Investigational Product (IP).</time_frame>
      <desc>Reported AEs are treatment-emergent AEs that is AEs that developed/worsened during the 'treatment-emergent period' (the time from the study drug dosing up to +30 days for non-serious AEs and +90 days for SAEs). Adverse Events do not include Study Endpoint Events. The Safety population included randomized participants who received any amount of the study drug dose of the double-blind IP infusion (summarized and analyzed as treated)- See Safety Population Milestone in Participant Flow Overview.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion&#xD;
Placebo</description>
        </group>
        <group group_id="E2">
          <title>PZ-128 0.3 mg/kg</title>
          <description>PZ-128, 0.3 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion&#xD;
PZ-128</description>
        </group>
        <group group_id="E3">
          <title>PZ-128 0.5 mg/kg</title>
          <description>PZ-128, 0.5 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion&#xD;
PZ-128</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <description>Unlikely related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <description>Unlikely related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <description>Unlikely related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Aortic Valve Disease</sub_title>
                <description>Unlikely related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <description>Unlikely related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Unlikely related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid Overload</sub_title>
                <description>Unlikely related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <description>Unlikely related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <description>Unlikely related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Possibly related to study drug</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypoesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Paresthesia Oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash Pruritic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Athan Kuliopulos, MD, PhD</name_or_title>
      <organization>Tufts Medical Center</organization>
      <phone>617-636-8482</phone>
      <email>athan.kuliopulos@tufts.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

